secwatch.observer — SEC 8-K summary
======================================

Issuer:     SKINVISIBLE, INC. (SKVI)
CIK:        0001085277
Form:       8-K
Filed at:   2025-01-23T23:59:59+00:00
Accession:  0001663577-25-000033
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skinvisible licensee Quoin reports positive Netherton Syndrome clinical results; $5M milestone payment upon approval
--------------------------------------------------------------------------------

- Quoin's QRX003 (using Invisicare) showed 'severe' to 'mild' improvement after 6 weeks in Netherton Syndrome studies.
- FDA cleared a whole-body study at Northwestern University; no adverse events reported to date.
- Clinical trials expanded to UK, Ireland, and Saudi Arabia; product licensed in 60 countries.
- Skinvisible to receive $5M milestone payment plus ongoing royalties upon FDA or EU approval.
- Skinvisible actively seeking partnerships for transdermal obesity therapies and other formulations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1085277/000166357725000033/0001663577-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1085277/000166357725000033/skvi8k_012325.htm
  HTML page:      https://secwatch.observer/filing/0001663577-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer